A Comparison of Presentation, Treatment, and Survival After Hepatocellular Carcinoma of Viral and Non-Viral Etiology in Damietta, Egypt, 2007–2019
DOI: https://doi.org/10.2147/jhc.s455832
2024-05-31
Journal of Hepatocellular Carcinoma
Abstract:Kévin Jean, 1– 3 Ahmed Tawheed, 4 Liem Binh Luong Nguyen, 5 Tarek Heikal, 6 Usama Eldaly, 6 Neveen Gaber Elhadidy, 7 Ahmed Elghaieb, 8 Ahmed Aboudonia, 8 Laura Tondeur, 5 Amélie Dublineau, 5 Arnaud Fontanet, 2, 5 Mohamed El-Kassas 4, 9 1 Laboratoire MESuRS, Conservatoire national des arts et métiers, Paris, France; 2 Unité PACRI, Institut Pasteur & Conservatoire national des arts et métiers, Paris, France; 3 IBENS, École Normale Supérieure, CNRS, INSERM, Université Paris Science & Lettres, Paris, France; 4 Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt; 5 Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France; 6 Medical Oncology Department, Damietta Oncology Center, Damietta, Egypt; 7 Pharmaceutical Services Department, Damietta Oncology Center, Damietta, Egypt; 8 Radiology Department, Damietta Oncology Center, Damietta, Egypt; 9 Clinical Research Centre, Air Force Specialized Hospital, Cairo, Egypt Correspondence: Kévin Jean, Laboratoire MESuRS, Conservatoire national des arts et métiers, 292 Rue Saint Martin, Paris, 75003, France, Email Context: The difference in prognosis between patients diagnosed with viral versus non-viral hepatocellular carcinoma (HCC) in Egypt remains unclear. Methods: We used data from patients diagnosed with HCC between 2007 and 2019 from a large monocentric retrospective cohort at the Damietta Oncology referral center (northern Egypt). Presentation and treatment were compared between viral versus non-viral etiology HCC patients. Survival was compared relying on univariate and multivariate Cox regressions. Results: Data from 4714 HCC patients were analyzed. Among them, 204 (4.3%) presented with a non-viral etiology. Patients with non-viral versus viral etiology had a similar presentation overall, especially regarding the BCLC stage at HCC diagnosis. After controlling for various individual characteristics, patients with non-viral versus viral etiology had poorer survival (adjusted Hazard Ratio: 1.244; 95% Confidence Interval: 1.069– 1.447). Conclusion: Despite similar features, patients with non-viral- related HCC had poorer survival compared to patients with viral-related HCC. Keywords: hepatocellular carcinoma, liver cancer, viral etiology, non-viral etiology, survival, epidemiology Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm globally, ranking as the fifth most prevalent form of cancer in males and the seventh in females. 1 The majority of HCC cases are caused by chronic liver disease resulting from infection with either hepatitis B virus (HBV) or hepatitis C virus (HCV), representing more than 80% of total cases of HCC. 2 In some geographical areas, there has been a notable decline in the occurrence of HCC recently. This decline may be linked to the expanding coverage of HBV vaccinations and the introduction of direct-acting antivirals (DAAs) for HCV. Meanwhile, there was a concomitant rise in the incidence of HCC in some Western countries, which could be attributed to the growing incidence of the metabolic syndrome and other related risk factors such as insulin resistance and obesity, and the associated increase in the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). 3,4 MASLD is currently considered the most prevalent chronic liver disease, nearly affecting one-third of the adult population worldwide. Moreover, about 3% to 5% of patients with MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH). Patients diagnosed with MASH are at a higher risk of developing end-stage liver disease and HCC, 4 which currently drives the increasing prevalence of HCC cases attributed to non-viral causes which has been reported in some countries. The unclear prognosis of individuals diagnosed with non-viral HCC compared to those with viral HCC is a topic that needs to be investigated. 5 The situation of the HCC epidemic is quite specific in Egypt, where HCC is the first most prevalent type of cancer in both sexes. 6 The high prevalence of HCV in Egypt significantly contributes to the increased HCC indices in the country, accounting for more than 90% of all HCC cases. 7 Moreover, over the past years, the Egyptian National Treatment Programs have conducted large HCV testing actions (screening for more than 65 million population over 8 months) and the linked HCC screening activities among those infected with HCV, especially cirrhotic patients. 8,9 -Abstract Truncated-
oncology